Global Research Output of Lutetium-177 PSMA in Prostate Cancer: Bibliometric and Altmetric Analyses

Al-Rashdan, Rakan; Al-Abdallat, Haneen; Sathekge, Mike Machaba; Mirzaei, Siroos; Shahait, Mohammed; Al-Khawaldeh, Khaled; Abdlkadir, Ahmed Saad; Lee, Szeting; Al-Ibraheem, Akram

doi:10.1055/a-2221-3036

Cited by 1 publication

(1 citation statement)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, if the disease progresses despite this therapy, mCRPC can develop [ 43 ]. The use of theranostic agents such as [ 177 Lu]Lu-PSMA is an emerging therapy for mCRPC that is available in many countries worldwide [ 44 , 45 ]. In parallel, [ 68 Ga]Ga-PSMA imaging can provide high diagnostic accuracy for disease staging, monitoring response, restaging, and assessing eligibility for PSMA RLT [ 46 , 47 , 48 ].…”

Section: Discussionmentioning

confidence: 99%

From Despair to Hope: First Arabic Experience of 177Lu-PSMA and 161Tb-PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer

Al-Ibraheem,

Abdlkadir,

Sweedat

et al. 2024

Cancers

Self Cite

View full text Add to dashboard Cite

The objective of this retrospective study is to assess the effectiveness and safety of two beta-emitting prostate-specific membrane antigen (PSMA) radioligands, [177Lu]Lu and [161Tb]Tb, in heavily treated patients with metastatic castration-resistant prostate cancer (mCRPC). A total of 148 cycles of beta-emitting PSMA radioligand therapy were given to 53 patients at a specialized cancer care center in Amman, Jordan. This treatment was offered following the exhaustion of all prior treatment modalities. Approximately half of the cases (n = 26) demonstrated an initial partial response to PSMA radioligand therapy. Moreover, roughly one-fourth of the patients (n = 13) exhibited a sustained satisfactory biochemical response, which qualified them to receive a total of six PSMA radioligand therapy cycles and maintain continued follow-up for additional treatment cycles. This was reflected by an adequate prostate-specific antigen (PSA) decline and a concomitant partial response evident on [68Ga]Ga-PSMA positron emission tomography/computed tomography imaging. A minority of patients (n= 18; 34%) experienced side effects. Generally, these were low-grade and self-limiting toxicities. This study endorses previous research evidence about PSMA radioligand therapy’s safety and efficacy. It also provides the first clinical insight from patients of Arab ethnicity. This should facilitate and promote further evidence, both regionally and internationally.

show abstract